Cannabix Technologies (CSE:BLO)(USOTC:BLOZF)(Frankfurt: 8CT)has announced a potentially transformative advancement in the field of breath-based drug testing, successfully detecting methamphetamine and amphetamine compounds in human breath samples using its proprietary Marijuana Breath Test (MBT) platform. The achievement highlights the growing versatility of the company’s technology and opens the door to significant new market opportunities beyond cannabis detection.
The breakthrough was achieved through the use of Cannabix’s Breath Collection Unit (BCU), with breath samples independently analyzed by Omega Laboratories utilizing highly sensitive liquid chromatography-mass spectrometry (LC-MS) techniques. The successful identification of methamphetamine and amphetamine in human breath demonstrates the ability of the Cannabix platform to capture and analyze substances that exist at extremely low concentrations.
This development represents an important validation of the company’s technology. Unlike urine or blood testing, breath contains only trace amounts of non-volatile drug compounds, making reliable detection a complex scientific challenge. The successful collection and identification of amphetamine-class stimulants suggests that Cannabix’s proprietary breath collection system is capable of capturing a broader range of substances than originally envisioned.
For investors and industry observers, the implications could be substantial. While the company’s Marijuana Breath Test has been primarily focused on detecting recent cannabis use, the ability to expand into stimulant detection significantly increases the addressable market. Industries such as transportation, construction, manufacturing, mining, and other safety-sensitive sectors continue to seek effective, non-invasive methods for monitoring drug impairment while maintaining operational efficiency and regulatory compliance.
Chief Executive Officer Rav Mlait emphasized the significance of the findings, noting that methamphetamine and amphetamine are particularly difficult compounds to detect in breath due to their extremely low concentrations. The early results reinforce the belief that Cannabix’s technology platform may ultimately support comprehensive breath-based drug testing solutions rather than serving as a single-purpose cannabis screening tool.
The potential commercial opportunity is compelling. Organizations across North America face increasing pressure to improve workplace safety and reduce impairment-related risks. Current testing methods often require invasive sample collection procedures and can present logistical challenges. Breath-based testing offers a rapid, non-invasive alternative that could improve compliance, streamline testing programs, and provide a more practical approach to impairment management.
Importantly, Cannabix’s system combines advanced breath collection hardware with a legally defensible chain-of-custody process and laboratory-based analytical methods. This combination may provide customers with a scientifically robust testing framework suitable for workplace safety programs, transportation operations, and law enforcement applications.
The announcement also reinforces Cannabix’s position as an innovator in the emerging breath diagnostics sector. The company’s technology portfolio already includes its Marijuana Breath Test and BreathLogix alcohol screening solution. Expanding the platform’s capabilities into additional drug categories could strengthen Cannabix’s competitive position and create multiple avenues for future growth.
As regulatory agencies, employers, and law enforcement organizations continue to seek more effective methods for detecting recent drug use and impairment, technologies capable of analyzing multiple substances through a single breath collection platform may become increasingly valuable. The successful detection of methamphetamine and amphetamine represents an important step toward that vision.
While additional testing and validation work will likely continue, this latest milestone demonstrates the adaptability of Cannabix’s technology and highlights its potential to address broader drug-testing challenges. For a company already focused on improving public safety through innovative breath analysis solutions, the expansion beyond THC detection could mark the beginning of a significant new phase of growth and market opportunity.
For more information visit – https://cannabixtechnologies.com/